AFRO News flags a downside of GLP-1 weight loss drugs that tends to get less attention. The full piece explains what doctors are watching for.
Recap by typeshit. Full story at AFRO News.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Dr Zack points to critics who attack physicians while wholesaling unlicensed research peptides that lack FDA approval.
FitPeo frames Ozempic, Zepbound and other GLP-1s as a useful tool rather than a fix, and stresses pairing them with solid eating habits.
Loading…